RenovoRx Inc. Expands Tumor Treatment Innovation with New Patent for TAMP Therapy Platform
Reuters
Aug 15
RenovoRx Inc. Expands Tumor Treatment Innovation with New Patent for TAMP Therapy Platform
RenovoRx Inc. has announced that its U.S. patent No. 12,290,564, titled "Methods for Treating Tumors," became effective on May 6. This patent expands the protection of methods for drug delivery using RenovoRx's TAMP therapy platform, facilitated by RenovoCath. It covers innovative methods for treating tumors by delivering drugs locally to a region of an artery or blood vessel near the tumor, following treatment to reduce the microvasculature. The patent provides protection through November 2037.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. RenovoRx Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20250814054147) on August 14, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.